OR WAIT 15 SECS
In the study, GigaGen presents a novel technology for producing a new class of drug, recombinant hyperimmunes, that may potentially generate new COVID-19 therapies.
GigaGen, a US-based biotechnology company specializing in antibody drugs for infectious diseases, transplant rejection, and checkpoint resistant cancers, submitted a new study, “Capturing and Recreating Diverse Antibody Repertoires as Multivalent Recombinant Polyclonal Antibody Drugs,” to bioRxiv, an online archive and distribution service, in which the company presents a novel technology for producing a new class of drug, which it has named "recombinant hyperimmunes," according to an Aug. 10, 2020 press release.
New data generated in GigaGen's study highlights the new class of drugs, which are polyclonal antibodies (recombinant hyperimmunes) that comprise thousands to tens of thousands of antibodies derived from donor B cells. The antibodies are produced recombinantly at large scale in mammalian cells.
The starting material for these polyclonal antibodies stems from convalescent serum. Convalescent serum therapies are being touted as a unique and viable approach to addressing the ongoing COVID-19 pandemic. Because these serum therapies comprise tens of thousands of antibodies, they have polyvalent activity against multiple drug targets and epitopes, which may improve clinical efficacy while taking advantage of in-vivo affinity maturation of the antibodies in the donors' immune systems. The system is modeled after other plasma-derived drugs, such as intravenous immunoglobulin (IVIG) and anti-thymocyte globulin (ATG), both currently used to treat significant patient populations worldwide.
Despite the promise these types of therapeutics hold, however, the drugs derived from blood fractions are difficult to manufacture consistently and at large scale. For example, in developing GigaGen’s potential drug candidate, GIGA-2050, the company's screen of 50 convalescent COVID-19 donors showed thousand-fold differences in anti-SARS CoV-2 titers. In addition, many donors are producing weak responses. This factor therefore significantly complicates the ability of convalescent serum manufacturers to acquire enough high-potency product to address the COVID-19 pandemic. The inconsistency seen in antibody responses to COVID-19 highlights the need to develop alternative therapeutic approaches in parallel to convalescent serum therapies, the company stated in the press release.
GIGA-2050 for treating COVID-19 has a similar result to recombinant convalescent serum, which combines the advantages of recombinant antibodies (e.g., purity, consistency, and potency) with the advantages of plasma-derived antibodies (e.g., proven efficacy, diversity, polyvalence, and in-vivo affinity maturation). GigaGen can produce millions of doses of drug using the new technology proposed in its study and without the need to recruit more convalescent donors.
Key results of the study include:
Beyond the use of recombinant hyperimmunes for treating COVID-19, the study data also suggested that this class of drug may have broad applicability through proofs-of-concept for a Zika hyperimmune therapy without the risk of antibody-dependent enhancement in? a high-potency spike-in mixture for primary immune deficiency, and a recombinant version of anti-human T-lymphocyte immunoglobulin for transplant tolerance.
“Our approach only requires a few donors to generate enough product to treat millions of people. No other company on Earth has the technology to produce this kind of drug. We still don't know whether vaccines and monoclonal antibodies will fail to prevent serious COVID-19, so our technology fills a critical niche to address the risk of a further escalating pandemic,” said David Johnson, PhD, co-founder and CEO of GigaGen, in the press release.